QCC374

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Healthy SubjectsPulmonary Arterial Hypertension

Phase 1

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374

CompletedNCT02245828

Novartis PharmaceuticalsHealthy Subjects

Start: 2014-07-31End: 2015-12-31Updated: 2016-03-22

Phase 2

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

TerminatedNCT02927366

Novartis PharmaceuticalsPulmonary Arterial Hypertension

Start: 2017-09-19End: 2018-06-07Updated: 2021-01-05

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

TerminatedNCT02939599

Novartis PharmaceuticalsPulmonary Arterial Hypertension

Start: 2018-02-01End: 2018-11-06Updated: 2021-01-05